1 / 66

DIC & Coagulation Disorders

DIC & Coagulation Disorders. Sarah McPherson & Mark Scott January 17, 2008. Objectives:. Physiology of coagulation Comparison of PLT vs. factor disorders Congenital Coagulopathies Basics of blood products and how much to give Trauma in the coagulopathic patient.

rory
Download Presentation

DIC & Coagulation Disorders

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. DIC & Coagulation Disorders Sarah McPherson & Mark Scott January 17, 2008

  2. Objectives: • Physiology of coagulation • Comparison of PLT vs. factor disorders • Congenital Coagulopathies • Basics of blood products and how much to give • Trauma in the coagulopathic patient. • Guidelines & Complications of Massive Transfusion • Indications for factor VIIa • Management of Iatrogenic coagulopathy • warfarin, heparin & thrombolytics • Special populations • Pediatrics • Pregnancy • What’s new?

  3. Hemostasis 101 Primary hemostasis - PLT mediated Secondary hemostasis - fibrin mediated

  4. Primary Hemostasisplatelet aggregation

  5. Primary Hemostasisplatelet plug

  6. Secondary Hemostasis Coagulation Cascade - Fibrin crosslinkage PeTPiTT bull

  7. Case 1 • 26 F G1P0 20 weeks gestation fever and skin rash • PE: T 385, purpura chest and legs, Fluctuating LOC and L hemiparesis. • Labs: Hg 100, PLTs 5, INR 1.0, PTT 31, schistocytes • Dx: TTP • Rx: ?

  8. PLTs vs Factors

  9. PLT Disorders Quantitative Qualitative Decreased Production Sequestration ASA, plavix renal and hepatic disease, vWD Destruction Immune Non-immune splenomegaly TTP DIC HUS HELLP Sepsis ITP Marrow failure

  10. ITP • Immune Thrombocytopenia purpura = acquired hemorrhagic dso with immune destruction of PLTs • Peaks in children 2-6 • Note: differing presentation in Adults vs. Children • Usually post viral IgG attack on PLTs Ag • PLT but functional • Sudden onset lasting a few weeks (rarely chronic) • Diagnosis of exclusion (usually no splenomegaly) • Suportive care for mild (PLT>50,000) • Tx for bleeding or PLT<20,000) • Steriods x 4 weeks +/- IVIG for mod/severe

  11. TTP • Thrombotic Thrombocytopenia Purpura = PLT deposition and aggr in capillaries • Presents with Thrombocytopenia, MAHA, (most common) Fever, purpura, neuro symptoms • Pregnancy (2nd Trim) is more common precipatant. Also sepsis, Malig, vasculitis, SLE, drugs • Labs show PLTs, schistocytes, HA, haptoglobin • Tx: Supportive + Plasmapheresis +/- steroids +/- splenectomy • 80-90% mortality if not treated

  12. Most Common: Heparin** Gold salts** Sulpha Quinine Ethanol (chronic)** ASA Indomethacin Valproate Rarely: Heroin Furosemide Procainamide Digoxin Ranitidine clopidogrel Drugs that cause Thrombocytopenia

  13. HUS • Hemolytic Uremic Syndrome = usually toxin mediated damage to renal tubules and glomerulus resulting in MAHA and PLT thrombi • Usually during or following diarrheal illness (EC 0157:H7) • Mortality 5-15%, worse in kids • Most common cause of renal failure in kids • Supportive Therapy +/- steriods

  14. DIC • Disseminated intravascular coagulation = sick pts. active TF causing massive microvascular deposition of fibrin accel thrombolysis and coagulation at same time • Results in consumption of PLTs, factors, fibrinogen, HA, production of FDPs • Clinical presention: • Multi-organ dysfunction form bleeding/coagulation • Renal failure, ACS, neuro abn, ARDS, ischemic colitis, etc • Extensive skin, incision and MM bleeding

  15. Etiology of DIC • Most common: sepsis (esp gm neg) • Cancer (remember Trousseau syndrome), adeno, Lymphoma. Leukemia • Trauma, post-op • Liver ds • Vascualr disease • Pregnancy • ARDS • Transfusion rxns • Toxins: snake bites, drugs, stimulants

  16. DIC labs • INR, D-dimer • PLTS • Fibrinogen • Schistocytes, fragmented RBCs • Renal failure • Hepatic failure

  17. DIC Treatment • Supportive and management of underlying Dso • Definitive TX depends on presentation • If Bleeding • Fibrinogen (~10u cryoprecipitate) • Factors (~4u FFP • PLTs if less than 50,000 (6u) • If Thrombosis (or purpura fulminans) • Heparin or LMWH • Protein C and AT III - under investigation

  18. Case 2 • 8 yo M present to PLC with painful swollen R knee 2 days after fight with his brother • Delayed bleeding from lacs • PE: R knee is swollen, erythematous, cool, remaining exam N. • Hg 140, PLTS 350, PTT = 90, INR 1.0 • Dx: Hemophilia • Tx: recombinant VIII

  19. Hemophilia • A  Deficiency of factor VIII (1 in 10,000 M) • B  Deficiency of factor IX (1 in 30,000 M) • Life-expectancy now 60yrs • X-linked recessive • Mild/moderate/severebased on percent of factor activity • >5%, 1-5%, <1% respectively • Most commonly hemarthrosis and SC bleeding

  20. Treatment for Hemophilia • Recombinant factor VIII • Dependent on severity • Mild 12.5u/kg • Moderate 25u/kg • Severe or signif bleeding 50u/kg • Go slow 3cc/min IV to avoid anaphylatoid rxn • Also consider: • FFP (200u per unit) • Cryoprecipitate (80u per unit) • 15% will develop alloantibodies (IgG) against FVIII which neutralize exogenous administration. Pts will require 3-4X the dose of replacement. • Give recombinant factor VIIa

  21. Von Willebrand Disease • Large multimeric glycoprotein involved in PLT aggregation and VIII • 1% of population • Type 1 - decr vWF (80%) • Type 2 - abn vWF • Type 3 - none (rare) • Usually asymptomatic unless challanged (surgery or trauma)

  22. Treatment for vWD • ddAVP • Induces release of vWF from endothelium • ? Secondary effect promoting hemostasis • 0.3ug/kg SC inj, max of 20ug every 12 hrs prn • Children - nasal spray • Cryoprecipitate second line or type 2 & 3 • Female pts can take OCP

  23. Case 3 • 79 M acute CVA presented 2hrs post onset • Nurse calls you to bedside re: Decr LOC • N CT head, stroke team involved • TPA was given 30mins prior • Tx: ?

  24. Management of Iatrogenic Coagulopathies • Warfarin (guilelines from “Chest” 2004) • INR 2-5 hold or reduce • INR 5-9 Vit K 1mg po • INR 9-20 Vit K 5mg po/IV • INR >20, or signif bleed FFP and Vit K 10mg po/IV • **be careful in High risk pts (Afib w/ VD, mech V) • Heparin & LWMH* • Thrombolytics

  25. Management of Iatrogenic Coagulopathies • Warfarin • Heparin • Protamine 1mg/100mg Hep in last 4 hrs • FFP • RBCs and PLTs if indicated • LMWH • Less bleeding complications • Protamine 1mg/1mg Enoxaparin • Thrombolytics

  26. Management of Iatrogenic Coagulopathies • Warfarin • Heparin & LWMH* • Thrombolytics - Converts Plasminogen to Plasmin • Stop TPA, stat CT head • Cryo +/- FFP +/- RBCs • +/- Transexamic acid 5g IV over 60mins, or • e-aminocaproic acid 10mg/kg q6H • Clopidogrel/ASA • Give PLTS (goal >50,000)

  27. Approach to Massively Bleeding Patient • ATLS • Target correction of CVP, MAP, Hg as in sepsis. • Mortiality benefit shown for correction of serum Lactate and pH Drummond et Al , 2001

  28. Clinically Significant Bleeding may occur if • INR >1.5 • PTT >55 • Fibrinogen <100mg/dL • PLTs <50

  29. Hemostasis Achieved if • Clotting factors approx >20-30% • Fibrinogen >100mg/dL • PLTs >50

  30. 1 Unit of Blood = 500cc • 225cc pRBCs • 225cc FFP • 50cc PLTs • 25cc cryoprecipitate

  31. Packed RBCs • 225cc concentrate RBCs, hct ~80-90% • 1 unit raises Hg by ~10mg/L • Oneg available immediately, typed blood 15mins, type and cross match 1 hr • Tranfuse if: • <70 & stable • <80 & bleeding • <100 & acute coronary syndrome

  32. FFP • Fluid portion of blood separated at 180C then frozen (~225cc) • Contains all Coag factors and some fibrinogen • 1 unit replaces approx 5-10% of factors • Should be ABO compatible • Give 4 u at a time

  33. Platelets • PLTs isolated from plasma (50cc) • Replace according to ABO compatibility • 1 unit will incr PLTs by approx 10 (variable) • Give 6u at a time

  34. Cryoprepitate • plasma fraction that contains factor VIII, vWF, fibrinogen (~50cc) • obtained by harvesting the precipitate that forms when frozen plasma is warmed to 4°C. • 1 bag contains approx 100U of vWF and FVIII • Used for bleeding if Fibrinogen <100, or VWD not responding to ddAVP • Give 10u at at time

More Related